QC
TGTX icon

Quadrature Capital’s TG Therapeutics TGTX Stock Holding History

Quadrature Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
20,140
+1,263
+7% +$51.7K 0.01% 704
2026
Q1 		$627K Buy
+18,877
New +$563K 0.01% 717
2025
Q2 		– Sell
-7,182
Closed -$283K – 1501
2025
Q1 		$283K Buy
+7,182
New +$242K 0.01% 754

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Quadrature Capital's TGTX Position: Q2 2026 in Review

Quadrature Capital increased its TG Therapeutics (TGTX) stake by 6.7% in Q2 2026, buying an estimated $51.7K and bringing the position to 20,140 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #704.

Quadrature Capital first reported a position in TGTX in Q1 2025 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Quadrature Capital held 20,140 shares of TG Therapeutics worth $1.11M as of Q2 2026.
  • Quadrature Capital bought 1,263 TG Therapeutics shares in Q2 2026, an estimated $51.7K.
  • TG Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #704 holding.
  • Quadrature Capital first reported a position in TG Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.